Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2020

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #1827

    Ja forståeligt nok.... Har ikke lige set det tidligere, men er noteret nu 😉

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Raun
      wrote on sidst redigeret af
      #1828

      Hvordan ser i på Genmab casen, som den ser ud d.d?...... Vi kan vel alle blive enige om at aktien er MEGET dyr på nøgletal. Men hvad er det egentlig der har gjort aktien så dyr?.... Der er vel 3 muligheder, som jeg ser det.... 1. Er det hedgefonde som handler den op?.... 2. Er det de institutionelle investorer som flytter deres penge fra obligationerne over i aktier, og hvad de ser som "sikre havne"... 3. Eller er det simpelthen bare en meget stor forventning til fremtiden?

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #1829

        Dyr? Estimeret PE for 2020 = 28

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #1830

          Men derudover der er tårnhøje forventninger til fremtiden...

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #1831

            Deutsche Bank Corporate Bank
            @DBCorporateBank
            ·Buoyed by the success of its blockbuster anticancer drug, read this flow article featuring @Genmab
            's CFO Anthony Pagano on how the Danish firm’s US capital raising fits that strategy https://cib.db.com/insights-and-initiatives
            /flow/trust-and-agency/antibody-builders.htm

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #1832

              Direkte link:
              https://cib.db.com/insights-and-initiatives/flow/trust-and-agency/antibody-builders.htm

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #1833

                Quarter end tomorrow, US Payroll numbers on Thursday with US holiday on Friday. could still be a fun week...

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1834

                  So if we close around here tomorrow, Genmab made around dkk700 in H1. Linear interpolation tells us we'll obviously do the same in H2, so we'll end the year at 2850 ish. So easy TA. 😉

                  1 Reply Last reply
                  0
                  • nohopeN Offline
                    nohopeN Offline
                    nohope
                    wrote on sidst redigeret af
                    #1835

                    Growth use to be exponential - so another 40-50 % in H2 would be a more accurate estimate....

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1836

                      ah offcourse, thanks for correcting that obvious mistake in my amazing analysis 😄

                      1 Reply Last reply
                      0
                      • nohopeN Offline
                        nohopeN Offline
                        nohope
                        wrote on sidst redigeret af
                        #1837

                        You are welcome 😉

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          BioShare
                          wrote on sidst redigeret af
                          #1838

                          Genmab har bare været super stærk igen i dag...der er efter min opfattelse helt klart et par store spillere på banen med kursmål betydeligt højere oppe. Ellers havde vi smidt højde i sidste uge...og i dag for den sags skyld.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #1839

                            it is just a sign of nohope's market influence; big players stepped in immediately after his comment 😉

                            1 Reply Last reply
                            0
                            • H Offline
                              H Offline
                              henrik48
                              wrote on sidst redigeret af
                              #1840

                              Helt enig...lad os slutte dagen med en forrygende slutauktion 🙂

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                BioShare
                                wrote on sidst redigeret af
                                #1841

                                ---haha...yes, and suddenly they saw hope and
                                that there were no errors in the spreadsheets 🙂

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  BioShare
                                  wrote on sidst redigeret af
                                  #1842

                                  Et fornuftigt luk i kurs 2.169 er meget tilfredsstillende - selvom volumen var relativ lav i dag. Lad se om US kan holde pace i løbet af aftenen, så skulle kurs 2.200 kommer i spil i morgen. VIX er også suset ned i forhold til tidligere på dagen, index ok...og NBI i bedring med et lille forsigtigt +-.

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #1843

                                    "We have moved to our new state-of-the-art offices and translational research laboratories! We look forward to welcoming our experts involved in discovery, development & commercialization of next-generation antibodytherapeutics to our new home, as per local guidance on COVID-19 https://twitter.com/Genmab/status/1277626056946724864
                                    .

                                    1 Reply Last reply
                                    0
                                    • H Offline
                                      H Offline
                                      HSK
                                      wrote on sidst redigeret af
                                      #1844

                                      Så’ der nyt

                                      1 Reply Last reply
                                      0
                                      • H Offline
                                        H Offline
                                        HSK
                                        wrote on sidst redigeret af
                                        #1845

                                        Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          HSK
                                          wrote on sidst redigeret af
                                          #1846

                                          24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger